William Josephson, MD
Internal Medicine · Northridge, CANPI 1376647651
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 342 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Lilly USA, LLC$731
- Abbott$510
- AstraZeneca$465
- Pfizer$449
- Teva Pharmaceuticals USA, Inc.$430
- plus $3K from 29 others
Across 14 payments — averaging $5245.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$73K
What the payments were for
- Travel & lodging$30%
- Food & beverage$7,459100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 80 | $1,506 |
| Lilly USA, LLC | 27 | $731 |
| Abbott | 23 | $510 |
| AstraZeneca | 25 | $465 |
| Pfizer | 25 | $449 |
| Teva Pharmaceuticals USA, Inc. | 18 | $430 |
| Boehringer Ingelheim | 10 | $349 |
| Novo Nordisk | 25 | $344 |
| Amarin Pharma, Inc. | 14 | $291 |
| Amgen | 10 | $239 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $238 |
| Sunovion Pharmaceuticals Inc. | 15 | $236 |
| Avanir Pharmaceuticals, Inc. | 15 | $226 |
| Nestle Healthcare Nutrition Inc. | 5 | $200 |
| Neurocrine Biosciences, Inc. | 3 | $167 |
| Exact Sciences | 2 | $147 |
| Bayer | 5 | $144 |
| GSK | 6 | $129 |
| Novartis | 4 | $109 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| AbbVie | 2 | $63 |
| Aimmune Therapeutics, Inc. | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Mannkind Corporation | 2 | $44 |
| Sun Pharmaceutical Industries Inc. | 2 | $35 |
| Indivior Inc. | 2 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $33 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Corcept Therapeutics | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,466 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $117,579 |
| JanuviaSitagliptin Phosphate | 130 | $95,303 |
| FarxigaDapagliflozin Propanediol | 133 | $94,612 |
| AustedoDeutetrabenazine | 25 | $88,146 |
| OzempicSemaglutide | 93 | $87,603 |
| JardianceEmpagliflozin | 79 | $80,906 |
| ZenpepLipase/Protease/Amylase | 24 | $49,283 |
| VascepaIcosapent Ethyl | 97 | $44,020 |
| MounjaroTirzepatide | 36 | $40,935 |
| KerendiaFinerenone | 40 | $39,940 |
| IngrezzaValbenazine Tosylate | 11 | $36,521 |
| XareltoRivaroxaban | 53 | $29,943 |
| CreonLipase/Protease/Amylase | 28 | $29,286 |
| EntrestoSacubitril/Valsartan | 54 | $27,686 |
| ValiumDiazepam | 12 | $17,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $449 | $117,579202 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $465 | $107,615166 claims |
| MerckJanuvia, Janumet Xr | $17 | $102,629143 claims |
| Boehringer IngelheimJardiance, Tradjenta | $349 | $92,113106 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $430 | $88,14625 claims |
| Novo NordiskOzempic | $344 | $87,60393 claims |
| Aimmune Therapeutics, Inc.Zenpep | $58 | $49,28324 claims |
| AbbVieCreon, Lumigan, Linzess | $63 | $43,07260 claims |
| Lilly USA, LLCMounjaro | $731 | $40,93536 claims |
| BayerKerendia | $144 | $39,94040 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $167 | $36,52111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $129 | $36,28282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Northridge
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.